Medindia

X

Japanese and French Firms Agree on Sharing Stem-Cell Research

by Rathi Manohar on  October 19, 2010 at 11:48 AM Genetics & Stem Cells News   - G J E 4
Cellectis SA of France, according to an agreement, can have access to a Japanese firm's patents on how to develop stem cells for medical treatment.
 Japanese and French Firms Agree on Sharing Stem-Cell Research
Japanese and French Firms Agree on Sharing Stem-Cell Research
Advertisement

iPS Academia Japan, which manages patents about use of so-called induced pluripotent stem cells, or iPS cells, signed the accord with the French biotechnology firm, Kyodo News reported without revealing the patent fee.

Advertisement
Under the accord Cellectis will test its drugs' performance and develop new therapeutic drugs using the iPS cells, which have the potential to grow into any type of body tissue, Kyodo said.

The iPS cells were developed by a Kyoto University team led by Professor Shinya Yamanaka. The university was granted the patents in September 2008 and then formed iPS Academia Japan to manage them.

The French firm is the third overseas company to conclude such an agreement, following Cellular Dynamics International Inc. of the United States and Axiogenesis AG of Germany, Kyodo said.

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All